Biophysical Journal 58: 471-481 (1990)
© 1990 the Biophysical Society

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Valdivia, H H Articles by Coronado, R Search for Related Content PubMed PubMed Citation Articles by Valdivia, H H Articles by Coronado, R

Direct binding of verapamil to the ryanodine receptor channel of sarcoplasmic reticulum.

Department of Physiology, University of Wisconsin School of Medicine, Madison 53706.

ABSTRACT

Radioligand binding experiments and single channel recordings demonstrate that verapamil interacts with the ryanodine receptor Ca2+ release channel of the sarcoplasmic reticulum of rabbit skeletal muscle. In isolated triads, verapamil decreased binding of [3H]Ryanodine with an IC50 of approximately 8 microM at an optimal pH 8.5 and pCa 4.3. Nitrendipine and d-cis-diltiazem did not interfere with binding of [3H]Ryanodine to triads, suggesting that the action of verapamil does not involve the dihydropyridine receptor. Single channel recordings showed that verapamil blocked Ca2+ release channels by decreasing open probability, duration of open events, and number of events per unit time. A direct interaction of verapamil with the ryanodine receptor peptide was demonstrated after purification of the approximately 400 kDa receptor protein from Chaps-solubilized triads. The purified receptor displayed high affinity for [3H]Ryanodine with a Kd of approximately 5 nM and a Bmax of approximately 400 pmol/mg. Verapamil and D600 decreased [3H]Ryanodine binding noncompetitively by reducing the Bmax. Thus the presence of binding sites for phenylalkylamines in the Ca2+ release channel was confirmed. Verapamil blockade of Ca2+ release channels may explain some of the paralyzing effects of phenylalkylamines observed during excitation-contraction coupling of skeletal muscle.

This article has been cited by other articles:

				N. Liu and S. G. Priori Disruption of calcium homeostasis and arrhythmogenesis induced by mutations in the cardiac ryanodine receptor and calsequestrin Cardiovasc Res, January 15, 2008; 77(2): 293 - 301. [Abstract] [Full Text] [PDF]

				K. Kontula, P. J. Laitinen, A. Lehtonen, L. Toivonen, M. Viitasalo, and H. Swan Catecholaminergic polymorphic ventricular tachycardia: Recent mechanistic insights Cardiovasc Res, August 15, 2005; 67(3): 379 - 387. [Abstract] [Full Text] [PDF]

				M. S. Islam The Ryanodine Receptor Calcium Channel of {beta}-Cells: Molecular Regulation and Physiological Significance Diabetes, May 1, 2002; 51(5): 1299 - 1309. [Abstract] [Full Text] [PDF]

				D. H. DiJulio, E. L. Watson, I. N. Pessah, K. L. Jacobson, S. M. Ott, E. D. Buck, and J. C. Singh Ryanodine Receptor Type III (Ry3R) Identification In Mouse Parotid Acini. PROPERTIES AND MODULATION OF [3H]RYANODINE-BINDING SITES J. Biol. Chem., June 20, 1997; 272(25): 15687 - 15696. [Abstract] [Full Text] [PDF]

				R. Zucchi and S. Ronca-Testoni The Sarcoplasmic Reticulum Ca2+ Channel/Ryanodine Receptor: Modulation by Endogenous Effectors, Drugs and Disease States Pharmacol. Rev., March 1, 1997; 49(1): 1 - 52. [Abstract] [Full Text] [PDF]

				J. Parness and S. S. Palnitkar Identification of Dantrolene Binding Sites in Porcine Skeletal Muscle Sarcoplasmic Reticulum J. Biol. Chem., August 4, 1995; 270(31): 18465 - 18472. [Abstract] [Full Text] [PDF]